Johns Hopkins ABX Guide
Telaprevir
INDICATIONS
FDA
FDA
In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed (no longer available in U.S.)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 9, 2018
Citation
Smith, Janessa, and Paul A Pham. "Telaprevir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir.
Smith J, Pham PA. Telaprevir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir. Accessed December 6, 2023.
Smith, J., & Pham, P. A. (2018). Telaprevir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir
Smith J, Pham PA. Telaprevir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2023 December 06]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telaprevir
ID - 540606
A1 - Smith,Janessa,Pharm.D. BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2018/02/09/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540606/all/Telaprevir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
